Who
David Smith V
Director
Company insider
Files Form 4 as: Director, Codexis; Director, IO Biotech; Executive Vice President & CFO, Five Prime Therapeutics; Director, Achieve Life Sciences; CFO & EVP, Thoratec; V.P. & Chief Financial Officer, Chiron.
In numbers
- Trades disclosed
- 108
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.4M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 16 Feb 2003
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —66,350 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —40,983 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | IO Biotechoption or derivative | SEC FORM 4 Code A | —35,144 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | CDXS CodexisChemicals | SEC FORM 4 Code A | —30,120 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | IO Biotechoption or derivative | SEC FORM 4 Code A | —45,642 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | CDXS CodexisChemicals | SEC FORM 4 Code G | —11,273 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | CDXS CodexisChemicals | SEC FORM 4 Code A | —34,602 at $0.00 | filing |
| 8 Jun 2023filed 13 Jun 2023 | IO Biotechoption or derivative | SEC FORM 4 Code A | —41,533 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | CDXS CodexisChemicals | SEC FORM 4 Code G | —4,796 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | CDXS CodexisChemicals | SEC FORM 4 Code A | —11,273 at $0.00 | filing |
| 26 May 2022filed 31 May 2022 | IO Biotechoption or derivative | SEC FORM 4 Code A | —23,885 at $0.00 | filing |
| 1 Mar 2022filed 3 Mar 2022 | IO Biotechoption or derivative | SEC FORM 4 Code A | —28,019 at $0.00 | filing |
| 15 Sep 2021filed 14 Jan 2022 | CDXS CodexisChemicals | SEC FORM 4 Code G | —4,000 at $0.00 | filing |
| 15 Jun 2021filed 17 Jun 2021 | CDXS CodexisChemicals | SEC FORM 4 Code G | —8,952 at $0.00 | filing |
| 15 Jun 2021filed 17 Jun 2021 | CDXS CodexisChemicals | SEC FORM 4 Code A | —4,796 at $0.00 | filing |
| 16 Apr 2021filed 19 Apr 2021 | Five Prime Therapeutics | SEC FORM 4 Code A | —66,000 at $0.00 | filing |
| 16 Apr 2021filed 19 Apr 2021 | Five Prime Therapeutics | SEC FORM 4 Code D | $5.3M138,947 at $38.00 | filing |
| 16 Apr 2021filed 19 Apr 2021 | Five Prime Therapeuticsoption or derivative | SEC FORM 4 Code D | —185,000 | filing |
| 16 Apr 2021filed 19 Apr 2021 | Five Prime Therapeuticsoption or derivative | SEC FORM 4 Code D | —90,000 | filing |
News
Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonCDXS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name David Smith V; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.